X4 Pharmaceuticals, a clinical stage biotechnology company developing a CXCR4 inhibitor to improve immune cell trafficking to treat cancer and rare diseases, announced updated results from the phase I part of an ongoing phase I/II study of X4P-001-IO in combination with Inlyta (axitinib) in patients with clear cell renal cell carcinoma.
Paul L. NguyenDiandra N. Ayala-PeacockStéphanie GaillardBradley CorrNRG Oncology named a new chair to the NRG Genitourinary Cancer Committee, a new vice-chair of the NRG Radiation Oncology Committee, and a new chair and vice-chair of the NRG Developmental Therapeutics Gynecologic Cancer Phase I Subcommittee.
